fda compounding semaglutide crackdown 2025 news How FDA Crackdowns Are Affecting GLP-1 Use In 2025

The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the

21.14

★★★★☆4.8 (126)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

28.59

★★★★★4.9 (98)

National Hispanic Medical Association | After compounded GLP-1 drugs were banned, counterfeit versions continued to circulate — and still do today. Understanding the risks and

21.84

★★★★★5.0 (157)

Compounded Semaglutide & Tirzepatide 2025: Safe Use Guide

22.92

★★★★★4.7 (84)

Compounded Semaglutide: Legal & Safe 2025

26.50

★★★★★4.9 (203)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

25.92

★★★★★5.0 (176)

Compounded medications are permitted by the FDA in times of shortage. That was present from 2021-2024 (tirzepatide) and 2025 (semaglutide). That has ended. The last two year grace period of continued

22.08

★★★★★4.8 (132)